SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
33.00    0.00 (0.00%)
Bid:
32.00
Ask:
34.00
Spread: 2.00 (6.25%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Key Technology Validation Milestone

2 Jul 2024 07:00

RNS Number : 6870U
Ilika plc
02 July 2024
 

Ilika plc

("Ilika" or the "Company")

 

Key Technology Validation Milestone

 

Ilika ships first batch of prototype Goliath batteries to automotive customer

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology, announces that it has shipped its first batch of prototype Goliath batteries for customer testing by a tier 1 automotive company.  

 

In May 2024, Ilika announced it had commenced in-house testing of its P1 Goliath prototype batteries in a customer-sponsored programme. Ilika has now shipped its first batch of P1 batteries to a customer for their external validation.

 

In November 2023, Ilika announced it had achieved its D4 development point, which is a design-freeze milestone in its Goliath roadmap upon which Ilika's first prototype for customer release, P1, is based. The P1 prototype is an intermediate milestone on Ilika's roadmap to its minimum viable product ("MVP") in 2025. The P1 prototype is a solid-state pouch cell with an NMC cathode and a silicon anode.

 

In line with the timeframe outlined when it published its last annual results in July 2023, Ilika confirms that it has successfully manufactured and tested batches of P1 pouch cells based on the D4 development point and is now engaged in a series of commercial programmes with automotive OEMs and Tier 1 companies.

 

Work is continuing on Ilika's roadmap through to MVP in CY25. Ilika's Goliath MVP, or P2 prototypes, will underpin licensing opportunities. Further detail regarding the product curve and development points can be found on page 11 of the Company's 2023 Annual Report, which is available by clicking here.

 

Graeme Purdy, Ilika CEO, stated: "Following up on the encouraging results from our P1 test programme, we are delighted to be engaging with a portfolio of interested OEMs and Tier 1 companies on commercially sponsored evaluation trials."

 

For more information contact:

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Via Walbrook PR

Jason Stewart, Chief Financial Officer

Panmure Liberum Limited (Nomad and Joint Broker)

Tel: 020 3100 2000

Andrew Godber, John More,

Nikhil Varghese, Josh Borlant

Joh. Berenberg, Gossler & Co. KG (Joint Broker)

Tel: 020 3207 8700

Mark Whitmore, Detlir Elezi,

Natasha Ninkov

Walbrook PR Ltd

Tel: 020 7933 8780 / Ilika@walbrookpr.com

Nick Rome

Mob: 07748 325 236

 

About Ilika plc - https://www.ilika.com.

Ilika specialises in the developing and commercialisation of solid state batteries. The Company's mission is to rapidly develop leading-edge IP, manufacture and license solid state batteries for markets that cannot be addressed with conventional batteries due to their safety, charge rates, energy density and life limits. The Company achieves this by using ceramic-based lithium-ion technology that is inherently safe in manufacture and usage, higher thermal tolerance and easier to recycle which differentiates our products from existing batteries.

 

The Company has two product lines. Its Stereax batteries which are designed for powering miniature medical implants, industrial wireless sensors and specialist internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFERDFILIIS
Date   Source Headline
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn
17th Nov 20229:00 amRNSPrice Monitoring Extension
17th Nov 20227:01 amRNSAppointment of Chief Financial Officer
17th Nov 20227:00 amRNSTrading Update, Notice of Results & Presentations
22nd Sep 202212:45 pmRNSExercise of Options, PDMR Shareholding and TVR
20th Sep 20224:47 pmRNSResult of AGM
7th Sep 202210:00 amRNSGoliath Scale-up Update
18th Aug 20227:00 amRNSPosting of Annual Report and Notice of AGM
1st Aug 20229:05 amRNSSecond Price Monitoring Extn
1st Aug 20229:00 amRNSPrice Monitoring Extension
25th Jul 20223:30 pmRNSHolding(s) in Company
20th Jul 20222:05 pmRNSSecond Price Monitoring Extn
20th Jul 20222:00 pmRNSPrice Monitoring Extension
14th Jul 20227:00 amRNSExercise of Options and Total Voting Rights
13th Jul 20224:41 pmRNSSecond Price Monitoring Extn
13th Jul 20224:36 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSGoliath Scale-up Update
11th May 20227:00 amRNSTrading Update & Notice of Results
4th May 20227:00 amRNSGoliath Scale-up Update
21st Mar 202211:45 amRNSDirector/PDMR Shareholding
15th Mar 202212:34 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSDirectorate Change
24th Feb 20222:01 pmRNSPrice Monitoring Extension
8th Feb 20227:00 amRNSAward of Share Options
7th Feb 202211:01 amRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSFirst Stereax Manufacturing Facility Opened
23rd Nov 20215:11 pmRNSHolding(s) in Company
19th Nov 20217:00 amRNSTrading Update & Notice of Half-year Results
10th Nov 20217:00 amRNSCapital Markets Day
22nd Sep 20213:30 pmRNSResult of AGM and Award of Bonus Share Options
10th Sep 20217:00 amRNSCommencement of trading on OTCQX Best Market in US
7th Sep 20217:00 amRNSSenior Appointments and Change of Director
24th Aug 20217:00 amRNSStereax Manufacturing Update
20th Aug 20217:00 amRNSNotice of AGM & Posting of Annual Report
5th Aug 20219:16 amRNSExercise of Options and Total Voting Rights
30th Jul 20214:32 pmRNSHolding(s) in Company
30th Jul 20219:54 amRNSDirector/PDMR Shareholding
29th Jul 20219:00 amRNSExercise of Options and Total Voting Rights
28th Jul 20211:14 pmRNSResults of GM, Open Offer and Total Voting Rights
12th Jul 202112:30 pmRNSPosting of Circular
9th Jul 20214:07 pmRNSResult of Placing and Retail Offer
9th Jul 20217:01 amRNSRetail Offer
9th Jul 20217:00 amRNSProposed Placing, Open Offer and Retail Offer
6th Jul 20217:00 amRNSFinal Results
5th Jul 202111:05 amRNSSecond Price Monitoring Extn
5th Jul 202111:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.